Insight into the heterogeneity of breast cancer through next-generation sequencing

Journal of Clinical Investigation

Volumn 121, Issue 10, 2011, Pages 3810-3818

  Russnes, Hege G ^a,b,c,d   Navin, Nicholas ^e   Hicks, James ^f   Borresen Dale, Anne Lise ^b,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CELL POPULATION; CLINICAL DECISION MAKING; DISEASE COURSE; GENE SEQUENCE; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOME ANALYSIS; HUMAN; PERSONALIZED MEDICINE; PHENOTYPE; PRIORITY JOURNAL; TREATMENT RESPONSE;

BREAST NEOPLASMS; DNA, NEOPLASM; FEMALE; GENETIC VARIATION; GENOME, HUMAN; HUMANS; INDIVIDUALIZED MEDICINE; MODELS, BIOLOGICAL; MUTATION; PHENOTYPE; PROGNOSIS; SEQUENCE ANALYSIS, DNA; TUMOR MARKERS, BIOLOGICAL;

EID: 80053393750     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI57088     Document Type: Article

References (106)

1. Mardis ER. A decade's perspective on DNA sequencing technology. Nature. 2011;470(7333):198-203.
2. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet. 2010;11(10):685-696.
3. Hudson TJ, et al. International network of cancer genome projects. Nature. 2010;464(7291):993-998.
4. Swanton C, Caldas C. Molecular classification of solid tumours: towards pathway-driven therapeutics. Br J Cancer. 2009;100(10):1517-1522.
5. Oakman C, Santarpia L, Di Leo A. Breast cancer assessment tools and optimizing adjuvant therapy. Nat Rev Clin Oncol. 2010;7(12):725-732.
6. Rakha EA, et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res. 2010;12(4):207.
7. Rakha EA, Reis-Filho JS, Ellis IO. Combinatorial biomarker expression in breast cancer. Breast Cancer Res Treat. 2010;120(2):293-308.
8. Perez EA. Breast cancer management: opportunities and barriers to an individualized approach. Oncologist. 2011;16 suppl 1:20-22.
9. Mardis ER. The $1,000 genome, the $100,000 analysis? Genome Med. 2010;2(11):84.
10. Pfeifer GP, Hainaut P. Next-generation sequencing: emerging lessons on the origins of human cancer. Curr Opin Oncol. 2011;23(1):62-68.
11. Elston CW, Ellis IO, Pinder SE. Prognostic factors in invasive carcinoma of the breast. Clin Oncol (R Coll Radiol). 1998;10(1):14-17. (Pubitemid 28112371)
12. The International Agency for Research on Cancer. World Health Organization: Tumors Of The Breast And Female Genital Organs (Who/iarc Classification Of Tumors). Tavassoéli FA, Devilee P, eds. Washington, DC, USA: IARC Press WHO; 2003.
13. Weigelt B, et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol. 2008;216(2):141-150.
14. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957;11(3):359-377.
15. van 't Veer LJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530-536.
16. van de Vijver MJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999-2009.
17. Wang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005;365(9460):671-679. (Pubitemid 40260888)
18. Sorlie T, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869-10874. (Pubitemid 32878711)
19. Perou CM, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.
20. Dunning MJ, Curtis C, Barbosa-Morais NL, Caldas C, Tavare S, Lynch AG. The importance of platform annotation in interpreting microarray data. Lancet Oncol. 2010;11(8):717.
21. Perou CM, Parker JS, Prat A, Ellis MJ, Bernard PS. Clinical implementation of the intrinsic subtypes of breast cancer. Lancet Oncol. 2010;11(8):718-719.
22. Sorlie T, et al. The importance of gene-centring microarray data. Lancet Oncol. 2010;11(8):719-720.
23. Weigelt B, et al. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol. 2010;11(4):339-349.
24. Sotiriou C, Piccart MJ. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer. 2007;7(7):545-553. (Pubitemid 46985399)
25. Hennessy BT, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial- to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009;69(10):4116-4124.
26. Gatza ML, et al. A pathway-based classification of human breast cancer. Proc Natl Acad Sci U S A. 2010;107(15):6994-6999.
27. Parker JS, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160-1167.
28. Nielsen TO, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res. 2010;16(21):5222- 5232.
29. Wirapati P, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008;10(4):R65.
30. Nielsen TO, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10(16):5367-5374. (Pubitemid 39100473)
31. Flagiello D, Gerbault-Seureau M, Sastre-Garau X, Padoy E, Vielh P, Dutrillaux B. Highly recurrent der(1;16)(q10;p10) and other 16q arm alterations in lobular breast cancer. Genes Chromosomes Cancer. 1998;23(4):300-306. (Pubitemid 28507369)
32. Tsarouha H, Pandis N, Bardi G, Teixeira MR, Andersen JA, Heim S. Karyotypic evolution in breast carcinomas with i(1)(q10) and der(1;16)(q10;p10) as the primary chromosome abnormality. Cancer Genet Cytogenet. 1999;113(2):156-161. (Pubitemid 29381553)
33. Gerbault-Seureau M, Vielh P, Zafrani B, Salmon R, Dutrillaux B. Cytogenetic study of twelve human near-diploid breast cancers with chromosomal changes. Ann Genet. 1987;30(3):138-145. (Pubitemid 17144092)
34. Pandis N, et al. Chromosome analysis of 97 primary breast carcinomas: identification of eight karyotypic subgroups. Genes Chromosomes Cancer. 1995;12(3):173-185.
35. Hicks J, et al. Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res. 2006;16(12):1465-1479. (Pubitemid 44878486)
36. Chin SF, et al. Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers. Oncogene. 2007;26(13):1959-1970.
37. Chin K, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 2006;10(6):529-541. (Pubitemid 44854748)
38. Bergamaschi A, et al. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol. 2008;214(3):357-367. (Pubitemid 351212391)
39. Russnes HG, et al. Genomic architecture characterizes tumor progression paths and fate in breast cancer patients. Sci Transl Med. 2010;2(38):38ra47.
40. Campbell PJ, et al. Identification of somatically acquired rearrangements in cancer using genomewide massively parallel paired-end sequencing. Nat Genet. 2008;40(6):722-729. (Pubitemid 351748860)
41. Hampton OA, et al. A sequence-level map of chromosomal breakpoints in the MCF-7 breast cancer cell line yields insights into the evolution of a cancer genome. Genome Res. 2009;19(2):167-177.
42. Stephens PJ, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell. 2011;144(1):27-40.
43. Stephens PJ, et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature. 2009;462(7276):1005-1010.
44. Ding L, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature. 2010;464(7291):999-1005.
45. Shah SP, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature. 2009;461(7265):809-813.
46. Berger MF, et al. The genomic complexity of primary human prostate cancer. Nature. 2011;470(7333):214-220.
47. Zhao H, et al. Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell. 2004;15(6):2523-2536. (Pubitemid 38691844)
48. Kan Z, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 2010;466(7308):869-873.
49. Ellis MJ, et al. Analysis of luminal-type breast cancer by massively parallel sequencing. Presented Saturday, April 2, 2011 at the 102nd Annual Meeting of the American Association for Cancer Research in Orlando, Florida, USA.
50. Sorlie T, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100(14):8418-8423. (Pubitemid 36842560)
51. Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle. 2004;3(10):1221-1224. (Pubitemid 40268595)
52. Langerod A, et al. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res. 2007;9(3):R30.
53. Stratton MR. Exploring the genomes of cancer cells: progress and promise. Science. 2011;331(6024):1553-1558.
54. Brown TM, Fee E. Rudolf Carl Virchow: medical scientist, social reformer, role model. Am J Public Health. 2006;96(12):2104-2105.
55. Fitzgerald PJ. Homogeneity and heterogeneity in pancreas cancer: presence of predominant and minor morphological types and implications. Int J Pancreatol. 1986;1(2):91-94. (Pubitemid 17047460)
56. Hirsch FR, Ottesen G, Podenphant J, Olsen J. Tumor heterogeneity in lung cancer based on light microscopic features. A retrospective study of a consecutive series of 200 patients, treated surgically. Virchows Arch A Pathol Anat Histopathol. 1983;402(2):147-153. (Pubitemid 14208540)
57. Kruger S, Thorns C, Bohle A, Feller AC. Prognostic significance of a grading system considering tumor heterogeneity in muscle-invasive urothelial carcinoma of the urinary bladder. Int Urol Nephrol. 2003;35(2):169-173. (Pubitemid 38418210)
58. van der Poel HG, Oosterhof GO, Schaafsma HE, Debruyne FM, Schalken JA. Intratumoral nuclear morphologic heterogeneity in prostate cancer. Urology. 1997;49(4):652-657. (Pubitemid 27161435)
59. Ignatiadis M, Sotiriou C. Understanding the molecular basis of histologic grade. Pathobiology. 2008;75(2):104-111. (Pubitemid 351820728)
60. Komaki K, Sano N, Tangoku A. Problems in histological grading of malignancy and its clinical significance in patients with operable breast cancer. Breast Cancer. 2006;13(3):249-253.
61. Farabegoli F, Santini D, Ceccarelli C, Taffurelli M, Marrano D, Baldini N. Clone heterogeneity in diploid and aneuploid breast carcinomas as detected by FISH. Cytometry. 2001;46(1):50-56. (Pubitemid 32216738)
62. Maley CC, et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet. 2006;38(4):468-473.
63. Mora J, Cheung NK, Gerald WL. Genetic heterogeneity and clonal evolution in neuroblastoma. Br J Cancer. 2001;85(2):182-189. (Pubitemid 32695737)
64. Pantou D, et al. Cytogenetic manifestations of multiple myeloma heterogeneity. Genes Chromosomes Cancer. 2005;42(1):44-57. (Pubitemid 39578664)
65. Roka S, et al. Aneuploidy of chromosome 8 as detected by interphase fluorescence in situ hybridization is a recurrent finding in primary and metastatic breast cancer. Breast Cancer Res Treat. 1998;48(2):125-133. (Pubitemid 28156357)
66. Sauter G, Moch H, Gasser TC, Mihatsch MJ, Waldman FM. Heterogeneity of chromosome 17 and erbB-2 gene copy number in primary and metastatic bladder cancer. Cytometry. 1995;21(1):40-46.
67. Teixeira MR, Pandis N, Bardi G, Andersen JA, Heim S. Karyotypic comparisons of multiple tumorous and macroscopically normal surrounding tissue samples from patients with breast cancer. Cancer Res. 1996;56(4):855-859. (Pubitemid 26055477)
68. Teixeira MR, Pandis N, Bardi G, Andersen JA, Mitelman F, Heim S. Clonal heterogeneity in breast cancer: karyotypic comparisons of multiple intra and extra-tumorous samples from 3 patients. Int J Cancer. 1995;63(1):63-68.
69. Park SY, Lee HE, Li H, Shipitsin M, Gelman R, Polyak K. Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res. 2010;16(3):876-887.
70. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995;270(5235):467-470.
71. Snijders AM, et al. Assembly of microarrays for genome-wide measurement of DNA copy number. Nat Genet. 2001;29(3):263-264. (Pubitemid 33096449)
72. Navin N, et al. Inferring tumor progression from genomic heterogeneity. Genome Res. 2010;20(1):68-80.
73. Shipitsin M, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007;11(3):259-273. (Pubitemid 46349843)
74. Keller PJ, et al. Mapping the cellular and molecular heterogeneity of normal and malignant breast tissues and cultured cell lines. Breast Cancer Res. 2010;12(5):R87.
75. Geigl JB, et al. Identification of small gains and losses in single cells after whole genome amplification on tiling oligo arrays. Nucleic Acids Res. 2009;37(15):e105.
76. Fuhrmann C, et al. High-resolution array comparative genomic hybridization of single micrometastatic tumor cells. Nucleic Acids Res. 2008;36(7):e39.
77. Fiegler H, et al. High resolution array-CGH analysis of single cells. Nucleic Acids Res. 2007;35(3):e15.
78. Klein CA, Schmidt-Kittler O, Schardt JA, Pantel K, Speicher MR, Riethmuller G. Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. Proc Natl Acad Sci U S A. 1999;96(8):4494-4499. (Pubitemid 29190364)
79. Navin N, et al. Tumour evolution inferred by single-cell sequencing. Nature. 2011;472(7341):90-94.
80. Campbell LL, Polyak K. Breast tumor heterogeneity: cancer stem cells or clonal evolution? Cell Cycle. 2007;6(19):2332-2338. (Pubitemid 350058682)
81. Visvader JE. Cells of origin in cancer. Nature. 2011;469(7330):314-322.
82. Polyak K. Breast cancer: origins and evolution. J Clin Invest. 2007;117(11):3155-3163. (Pubitemid 350096968)
83. Bloushtain-Qimron N, et al. Cell type-specific DNA methylation patterns in the human breast. Proc Natl Acad Sci U S A. 2008;105(37):14076-14081.
84. Holm K, et al. Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res. 2010;12(3):R36.
85. Kamalakaran S, et al. DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables. Mol Oncol. 2011;5(1):77-92.
86. Ronneberg JA, et al. Methylation profiling with a panel of cancer related genes: Association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer. Mol Oncol. 2011;5(1):61-76.
87. Lim E, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med. 2009;15(8):907-913.
88. Molyneux G, et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell. 2010;7(3):403-417.
89. Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta. 2010;1805(1):105-117.
90. Navin NE, Hicks J. Tracing the tumor lineage. Mol Oncol. 2010;4(3):267-283.
91. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194(4260):23-28.
92. Loeb LA, Springgate CF, Battula N. Errors in DNA replication as a basis of malignant changes. Cancer Res. 1974;34(9):2311-2321.
93. Paik S, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817-2826. (Pubitemid 40051905)
94. Desmedt C, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008;14(16):5158-5165.
95. Stuart D, Sellers WR. Linking somatic genetic alterations in cancer to therapeutics. Curr Opin Cell Biol. 2009;21(2):304-310.
96. Gerlinger M, Swanton C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer. 2010;103(8):1139-1143.
97. Merlo LM, et al. A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev Res (Phila). 2010;3(11):1388-1397.
98. Cooke SL, et al. Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Oncogene. 2010;29(35):4905-4913.
99. Cooke SL, et al. Intra-tumour genetic heterogeneity and poor chemoradiotherapy response in cervical cancer. Br J Cancer. 2011;104(2):361-368.
100. Jones SJ, et al. Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. Genome Biol. 2010;11(8):R82.
101. Braun S, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005;353(8):793-802. (Pubitemid 41215488)
102. Naume B, et al. Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer. Mol Oncol. 2007;1(2):160-171. (Pubitemid 47199130)
103. Wiedswang G, et al. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol. 2003;21(18):3469-3478. (Pubitemid 46594079)
104. Leary RJ, et al. Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med. 2010;2(20):20ra14.
105. McBride DJ, et al. Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes Cancer. 2010;49(11):1062-1069.
106. Beck J, Urnovitz HB, Mitchell WM, Schutz E. Next generation sequencing of serum circulating nucleic acids from patients with invasive ductal breast cancer reveals differences to healthy and nonmalignant controls. Mol Cancer Res. 2010;8(3):335-342.